Teprotumumab shows promise in small chinese thyroid eye study
NCT ID NCT07085117
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study looked at how well teprotumumab (TEPEZZA) works in real-world use for 5 Chinese patients with thyroid eye disease. The main goal was to see how many patients had a reduction in eye bulging (proptosis) after their last IV infusion. The study also collected basic information about the patients and their health at the start of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- teprotumumab (TEPEZZA)
- What this could lead to
- If successful, this could confirm that teprotumumab works in Chinese patients with thyroid eye disease, supporting its use in broader populations.
- What could go wrong
- This is a very small study (only 5 patients) and retrospective, so results may not apply to everyone. No new safety data beyond what is already known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boao Vanguard Hospital
Qionghai, Hainan, 571400, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody calm thyroid eye disease?
- Could a cholesterol drug shrink eye muscle swelling in thyroid eye disease?
- Can an experimental drug reduce eye bulging in thyroid eye disease?
- Can a new drug ease bulging eyes in thyroid disease?
- New drug IBI3031 enters first human trial for thyroid eye disease
- New hope for thyroid eye disease: drug shows promise in Steroid-Resistant patients